Trials / Completed
CompletedNCT04342273
A Through QT/QTc Study of KW-6356
A Through QT/QTc Study of KW-6356 in Japanese Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 128 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 54 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effects of multiple therapeutic and supratherapeutic doses of KW-6356 on the QT interval corrected for heart rate in Japanese healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KW-6356 | KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7 |
| DRUG | KW-6356 | KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7 |
| DRUG | Placebo | Placebo will be administered once daily at Day 1 through Day 7 |
| DRUG | Moxifloxacin | Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7. |
Timeline
- Start date
- 2020-03-31
- Primary completion
- 2020-09-05
- Completion
- 2020-09-05
- First posted
- 2020-04-13
- Last updated
- 2020-09-18
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04342273. Inclusion in this directory is not an endorsement.